Quote:
Originally Posted by Chris
In D A Green's analysis it still comes back to whether or not AstraZeneca's existing capacity in the UK can be regarded as part of the capacity from which it is obliged to deliver product to the EU. One comment from the EU that he seems to have missed is their attempt to claim that EU development funds have been used in the UK. This suggests to me that the EU thinks it can only claim a share of UK product on the basis that they helped fund its manufacture - i.e. the poduct's mere existence as part of AstraZeneca's capacity to supply is not enough.
|
This is key.
Was EU money used only to set up & develop the facilities in the EU only. If so then there is no argument or claim to be had from the EU.
IF AZ did use UK & EU money to set up production in the UK, EU could claim a % of the output based on a % of funding.
This will rattle on for a while, lawyers will be licking their lips, but it won't get resolved quickly and I would hope that at the speed we're going we'll have all had our shots from one of the many vaccines in the pipeline by the time it's resolved.